1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
Catheter-Related Bloodstream Infection (CRBSI) -Market Insights, Epidemiology, and Market Forecast-2028

Catheter-Related Bloodstream Infection (CRBSI) -Market Insights, Epidemiology, and Market Forecast-2028

  • April 2020
  • 225 pages
  • ID: 5875498
  • Format: PDF
  • Delve Insight

Summary

Table of Contents

‘Catheter-Related Bloodstream Infection (CRBSI) -Market Insights, Epidemiology, and Market Forecast-2028’ report delivers an in-depth understanding of the catheter-related bloodstream infection, historical and forecasted epidemiology as well as the catheter-related bloodstream infection market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), Japan, APAC (China, India, Taiwan, South Korea, and Australia), LATAM (Brazil, Mexico, Argentina, and Colombia), Middle East (Saudi Arabia and the United Arab Emirates), and Russia.

Geography Covered
• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan
• APAC (China, India, Taiwan, South Korea, and Australia)
• LATAM (Brazil, Mexico, Argentina, and Colombia)
• Middle East (Saudi Arabia and the United Arab Emirates)
• Russia

Study Period: 2017–2028
Catheter-Related Bloodstream Infection: Disease Understanding and Treatment Algorithm
Catheter-Related Bloodstream Infection Overview
Catheter-related bloodstream infection also known as catheter-related sepsis, defined as the presence of bacteremia originating from a catheter insertion. Antibiotics such as antibacterial and antifungal are used for the treatment of the disease. Antibiotic lock therapy is considered as adjunctive therapy in the treatment of CRBSI when catheter removal is not a favorable option. The current treatment options are used as off-label therapies and only a few non-antibiotic lock solutions are approved in Europe.

Catheter-Related Bloodstream Infection Diagnosis
The diagnosis of catheter-related bloodstream infection remains a major challenge. Fever and chills that are often associated with catheter-related bloodstream infections are not specific. Furthermore, local catheter inflammation and phlebitis could exist in the absence of catheter-related bloodstream infection or even a local infection, as has been reported with peripherally inserted central catheters. The ‘gold standard’ for the diagnosis of catheter-related bloodstream infection is the combination of positive blood culture with the same organism isolated from the catheter. However, a major diagnostic problem is that traditional methods of catheter culture necessitate the removal of the central venous catheters (CVC), whereby the line tip is either rolled on an agar plate or placed in a nutrient broth.

Catheter-Related Bloodstream Infection Treatment
It covers the details of conventional and current medical therapies available in the catheter-related bloodstream infection market for the treatment of the condition. It also provides the treatment guidelines and algorithms of the United States and Spain.
The’s catheter-related bloodstream infection market report gives a thorough understanding of catheter-related bloodstream infection by including details such as disease definition, causes, risk factors, pathogenesis, and diagnosis.

Catheter-Related Bloodstream Infection Epidemiology
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Incident Population of Catheter-Related Bloodstream Infection Total Diagnosed Incident Population of Catheter-Related Bloodstream Infection, and Diagnosed Incidence of Catheter-Related Bloodstream Infection by Causative Pathogens scenario of catheter-related bloodstream infection in the global market covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom), Japan, APAC (China, India, Taiwan, South Korea, and Australia), LATAM (Brazil, Mexico, Argentina, and Colombia), Middle East (Saudi Arabia and the United Arab Emirates), and Russia from 2017 to 2028.

Key Findings
This section provides glimpses of the catheter-related bloodstream infection epidemiology in the global market.
As per the analysis, the total incident population of catheter-related bloodstream infection in the global market was found to be 4,114,882 in 2017. The estimates show a higher incidence of catheter-related bloodstream infection in India with 1,722,280 cases in 2017.

Country Wise- Catheter-Related Bloodstream Infection Epidemiology
The epidemiology segment also provides the catheter-related bloodstream infection epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), Japan, APAC (China, India, Taiwan, South Korea, and Australia), LATAM (Brazil, Mexico, Argentina, and Colombia), Middle East (Saudi Arabia and the United Arab Emirates), and Russia.
Catheter-Related Bloodstream Infection Drug Chapters
The drug chapter segment of the catheter-related bloodstream infection report encloses the detailed analysis of catheter-related bloodstream infection marketed drugs and late stage (phase III) pipeline drugs. It also helps to understand the catheter-related bloodstream infection clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
Catheter-Related Bloodstream Infection Marketed Drugs
Neutrolin: CorMedix
Neutrolin (CRMD003), is a non-antibiotic, anti-infective developed by CorMedix as a preventative solution to decrease the threat of infection and blood clots (thrombosis), thereby keeping CVCs operating safely and efficiently. It is a catheter lock solution for the prevention of catheter-related bloodstream infection and maintenance of catheter patency in hemodialysis patients.
Taurosept: Geistlich Pharma
TauroSept is an antimicrobial solution (lock solution) developed by Geistlich Pharma for the prevention of catheter-related infection and is intended for installation in intravenous catheters between treatments to lock the catheter. It mainly contains antibacterial chemotherapeutic agent taurolidine.
Products detail in the report…
Catheter-Related Bloodstream Infection Off-label Drugs
Daptomycin
Daptomycin is a cyclic lipopeptide parenteral antibiotic derived from Streptomyces roseosporus. It exhibits rapid concentration-dependent bactericidal activity against Gram-positive pathogens such as methicillin-resistant Staphylococcus aureus (MRSA).
Vancomycin
Vancomycin is a tricyclic glycopeptide antibiotic originally derived from the organism Streptococcus orientalis. Vancomycin is used for the treatment and prevention of various bacterial infection caused by Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA).
Products detail in the report…

Catheter-Related Bloodstream Infection Emerging Drugs
Mino-Lok: Citius Pharmaceuticals
Mino-Lok is an antibiotic lock solution used to treat patients with central line-associated bloodstream infection/catheter-related bloodstream infection. It is a combination of minocycline, edetate (disodium EDTA), and ethyl alcohol, all of which act synergistically to break down bacterial biofilms, eradicate the bacteria, provide anti-clotting properties to maintain patency in CVCs, and salvage the indwelling catheter.
Products detail in the report…

Catheter-Related Bloodstream Infection Market Outlook
The catheter-related bloodstream infection market outlook of the report helps to build a detailed comprehension of the historic, current and forecasted catheter-related bloodstream infection market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers, and demand of better technology.
This segment gives a thorough detail of catheter-related bloodstream infection market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to the report, catheter-related bloodstream infection global market is expected to change in the study period 2017–2028.

Key Findings
This section includes a glimpse of the catheter-related bloodstream infection global market. The market size of CRBSI in the Global market was USD 1,237.38 million in 2017.

The United States Market Outlook
This section provides the total catheter-related bloodstream infection market size and market size by therapies in the United States.
Among the Global Market, the United States had the highest market size of CRBSI in 2017, which accounts for approximately 55% of the total market. The growth of market size for CRBSI is attributed to currently prescribed treatment regimens as well as emerging therapies. The market size for CRBSI was found to be USD 381.5 million in 2017.

EU-5 Market Outlook
The total catheter-related bloodstream infection market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.

Japan Market Outlook
The total catheter-related bloodstream infection market size and market size by therapies in Japan are provided.

APAC Market Outlook
The total catheter-related bloodstream infection market size and market size by therapies in China, India, Taiwan, South Korea, and Australia are provided in this section.
India accounts for approximately 34.7% of the total APAC market of CRBSI. Our estimations suggest that the overall market size of CRBSI will increase at a moderate pace with USD 178.72 million in 2017 to USD 189.32 million in 2022. This is due to the dependency on the market size of CRBSI on supportive treatment regimens.

LATAM Market Outlook
The total catheter-related bloodstream infection market size and market size by therapies in Brazil, Mexico, Argentina, and Colombia are provided.
Argentina accounts for 13.7% of the total LATAM market of CRBSI. Our estimations suggest that the overall market size of CRBSI will grow with USD 8.59 million in 2017 to USD 9.23 million in 2022. This is attributed to the dependency on the market size of CRBSI on supportive therapies for CRBSI.

Middle East Market Outlook
The total catheter-related bloodstream infection market size and market size by therapies in Saudi Arabia and the United Arab Emirates are provided in this section.

Russia Market Outlook
The total catheter-related bloodstream infection market size and market size by therapies in Russia are provided in this section.

Catheter-Related Bloodstream Infection Drugs Uptake
This section focusses on the rate of uptake of the potential drugs recently launched in the catheter-related bloodstream infection market or expected to get launched in the market during the study period 2017–2028. The analysis covers catheter-related bloodstream infection market uptake by drugs; patient uptake by therapies; and sales of each drug.

Catheter-Related Bloodstream Infection Development Activities
The report provides insights into different therapeutic candidates in phase II, and phase III stage. It also analyzes key players involved in developing targeted therapeutics.

Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition, and merger, licensing and patent details for catheter-related bloodstream infection emerging therapies.
Reimbursement Scenario in Catheter-Related Bloodstream Infection
Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In the report, we consider reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.
KOL- Views
To keep up with current market trends, we take KOLs and SME’s opinion working in catheter-related bloodstream infection domains through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or catheter-related bloodstream infection market trends. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis
We perform competitively and market Intelligence analysis of the catheter-related bloodstream infection market by using various competitive intelligence tools that include–SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report
• The report covers the descriptive overview of catheter-related bloodstream infection, explaining its causes, signs and symptoms, pathogenesis and currently available therapies.
• Comprehensive insight has been provided into the catheter-related bloodstream infection epidemiology and treatment.
• Additionally, an all-inclusive account of both the current and emerging therapies for catheter-related bloodstream infection are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
• A detailed review of catheter-related bloodstream infection market; historical and forecasted is included in the report, covering the global drug outreach.
• The report provides an edge while developing business strategies, by understanding trends shaping and driving the global catheter-related bloodstream infection market

Report Highlights
• In the coming years, catheter-related bloodstream infection market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies and academics are working to assess challenges and seek opportunities that could influence catheter-related bloodstream infection R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
• Major players are involved in developing therapies for catheter-related bloodstream infection. Launch of emerging therapies will significantly impact the catheter-related bloodstream infection market
• Our in-depth analysis of the pipeline assets across different stages of development (phase III and phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.
Catheter-Related Bloodstream Infection Report Insights
• Patient Population
• Therapeutic Approaches
• Catheter-Related Bloodstream Infection Pipeline Analysis
• Catheter-Related Bloodstream Infection Market Size and Trends
• Market Opportunities
• Impact of upcoming Therapies

Catheter-Related Bloodstream Infection Report Key Strengths
• Nine Years Forecast
• Global Coverage

• Catheter-Related Bloodstream Infection Epidemiology Segmentation
• Key Cross Competition
• Highly Analyzed Market

• Drugs Uptake

Catheter-Related Bloodstream Infection Report Assessment
• Current Treatment Practices
• Unmet Needs
• Pipeline Product Profiles
• Market Attractiveness
• Market Drivers and Barriers

Key Questions

Market Insights:
• What was the catheter-related bloodstream infection market share (%) distribution in 2017 and how it would look like in 2028?
• What would be the catheter-related bloodstream infection total market size as well as market size by therapies across the globe during the forecast period (2020–2028)?
• What are the key findings pertaining to the market across the globe and which country will have the largest catheter-related bloodstream infection market size during the forecast period (2020–2028)?
• At what CAGR, the catheter-related bloodstream infection market is expected to grow at the global level during the forecast period (2020–2028)?
• What would be the catheter-related bloodstream infection market outlook across the globe during the forecast period (2020–2028)?
• What would be the catheter-related bloodstream infection market growth till 2028 and what will be the resultant market size in the year 2028?
• How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:
• What is the disease risk, burden and unmet needs of catheter-related bloodstream infection?
• What is the historical catheter-related bloodstream infection patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK), Japan, APAC (China, India, Taiwan, South Korea, and Australia), LATAM (Brazil, Mexico, Argentina, and Colombia), Middle East (Saudi Arabia and the United Arab Emirates), and Russia?
• What would be the forecasted patient pool of catheter-related bloodstream infection at the global level?
• What will be the growth opportunities across the globe concerning the patient population about catheter-related bloodstream infection?
• Out of the above-mentioned countries, which country would have the highest Incident population of catheter-related bloodstream infection during the forecast period (2020–2028)?
• At what CAGR the population is expected to grow across the globe during the forecast period (2020–2028)?

Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:
• What are the current options for the treatment of catheter-related bloodstream infection along with the approved therapy?
• What are the current treatment guidelines for the treatment of catheter-related bloodstream infection in the US and Spain?
• What is the catheter-related bloodstream infection marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, and efficacy, etc.?
• How many companies are developing therapies for the treatment of catheter-related bloodstream infection?
• How many therapies are developed by each company for the treatment of catheter-related bloodstream infection?
• How many emerging therapies are in the mid-stage and late stages of development for the treatment of catheter-related bloodstream infection?
• What are the key collaborations (Industry–Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the catheter-related bloodstream infection therapies?
• What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for catheter-related bloodstream infection and their status?
• What are the key designations that have been granted for the emerging therapies for catheter-related bloodstream infection?
• What are the global historical and forecasted market of catheter-related bloodstream infection?

Reasons to buy
- The report will help in developing business strategies by understanding trends shaping and driving the catheter-related bloodstream infection.
- To understand the future market competition in the catheter-related bloodstream infection market and Insightful review of the key market drivers and barriers.
- Organize sales and marketing efforts by identifying the best opportunities for catheter-related bloodstream infection in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom), Japan, APAC (China, India, Taiwan, South Korea, and Australia), LATAM (Brazil, Mexico, Argentina, and Colombia) and Middle East (Saudi Arabia and the United Arab Emirates) and Russia.
- Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
- Organize sales and marketing efforts by identifying the best opportunities for catheter-related bloodstream infection market.
- To understand the future market competition in the catheter-related bloodstream infection market.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.

ref:plp2020

Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on